Status:
COMPLETED
Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Cisplatin-based combination chemotherapy given concurrently with radiotherapy is the standard of care for patients with inoperable stage III NSCLC. The most common chemotherapeutic agents used concurr...
Eligibility Criteria
Inclusion
- Inoperable stage IIIA/IIIB NSCLC proved by pathology or cytology
- Age 18 to 75, ECOG ≤ 2, lose weight \<10% during 6 months
- No serious diseases of important organs
- Chest CT in recently 4 weeks
- No other tumor disease except stage I cervical cancer or cutaneous basal cell carcinoma
- Sign consent
- Measurable lesion
Exclusion
- Pretreatment radiotherapy or chemotherapy
- Pregnant or lactation woman
- Serious diseases (include uncontrolled diabetes and infection) of important organs
- Psychopath
- Join in other clinical trial
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01494558
Start Date
May 1 2007
End Date
August 1 2011
Last Update
December 19 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.